Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Serdemetan is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.
Description | Serdemetan is an orally bioavailable HDM2 antagonist with potential antineoplastic activity. |
Targets&IC50 | REH cells:0.44 μM, OCI-AML-3:0.24 μM, MOLM-13:0.33 μM, NALM-6:0.32 μM |
Cell Research | Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK(Only for Reference) |
Synonyms | N-[2-(1H-吲哚-3-基)乙基]-N'-(4-吡啶基)-1,4-苯二胺, JNJ-26854165 |
Molecular Weight | 328.419 |
Formula | C21H20N4 |
CAS No. | 881202-45-5 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ethanol: 2 mg/mL (6.08 mM)
H2O: <1 mg/mL
DMSO: 61 mg/mL (185.7 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Serdemetan 881202-45-5 凋亡 泛素化 Apoptosis E1/E2/E3 Enzyme Mdm2 p53 JNJ 26854165 E3 ligating enzyme Ubiquitin activating enzyme E1 activating enzyme Ubiquitin ligase Inhibitor E2 conjugating enzyme JNJ26854165 inhibit JNJ-26854165 Ubiquitin conjugating enzyme MDM-2/p53 inhibitor